ea0098c3 | Clinical – Chemo/SSA/Biologics | NANETS2023
Paulo Solar Vasconcelos Joao
, Eduardo Nunez Rodrigues Jose
, Zaidi Ali
, Jafari Helia
, Krishnan Tharani
, Gill Sharlene
, Tan Ann
, Le Dan
, Chan Theresa
, Yu Simon
, Paul McGhie John
, Lim Howard
, Singh Simron
, Michael Loree Jonathan
Background: Metastatic neuroendocrine neoplasms (NENs) constitute a heterogeneous group of uncurable cancers with limited treatment options. Lenvatinib is an oral multiple kinase inhibitor that showed activity in gastroenteropancreatic neuroendocrine tumors in the phase II Talent Trial at a starting dose of 24 mg per day. Although a confirmatory phase III study was never conducted, the drug is available for use off-label.Methods: We retrospectively revie...